China Bribery Probe Not Fair To Foreign Companies, EU Chamber Of Commerce Says
This article was originally published in PharmAsia News
China’s ongoing investigation on commercial bribery is being handled disproportionately among foreign firms and domestic ones, European companies say. Still, they are willing to collaborate with the government to improve the system if given a platform.
You may also be interested in...
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.
Facing the aftermath of coronavirus disruption and supply chain reorganization, executives of multinational drug firms in China say the government needs to do more to help address a flurry of issues laid bare by the public health crisis.